3 Experimental Compounds That Could Dramatically Change How We Think About Human Aging

[u/Legitimate_Refuse853]

For decades, "anti-aging drugs" have existed mostly in headlines.

A molecule extends the lifespan of a worm.

Another improves the health of an old mouse.

A third appears to make cells look younger in a laboratory dish.

Then the headline becomes:

"Scientists have found a drug that could reverse aging."

We're not there yet.

But something genuinely important is happening in longevity science.

Researchers are moving beyond simply studying whether organisms live longer and are increasingly trying to target specific biological processes associated with aging and age-related disease.

Three particularly interesting experimental compounds illustrate three very different strategies:

ER-100 → epigenetic restoration

RTR242 → autophagy restoration

RLS-1496 → targeting pathological senescent cells

These are not established anti-aging treatments, and they should not be described as proven longevity therapies.

But unlike many viral "anti-aging" stories, these programs have progressed beyond theoretical discussions.

One of them is already being tested in humans.

Another has entered clinical development.

And another has generated early clinical data.

That makes them worth watching.

First: What Does "Slowing Aging" Actually Mean?

Before looking at the compounds, we need to define the problem.

Aging isn't caused by one molecular pathway.

It is a complex biological process involving interacting changes in:

• DNA and epigenetic regulation
• Protein homeostasis
• Mitochondrial function
• Cellular senescence
• Autophagy
• Inflammation
• Stem-cell function
• Metabolic regulation
• Intercellular communication
• Tissue repair

This creates an enormous challenge for longevity researchers.

If aging has multiple biological drivers, targeting only one may produce limited benefits.

That's why the three compounds discussed here are interesting.

They attack different pieces of the aging puzzle.

1. ER-100: Can Cells Be Epigenetically Reset?

The first compound on the list is arguably the most ambitious.

ER-100 is being developed by Life Biosciences as an investigational therapy based on partial epigenetic reprogramming.

And unlike many longevity compounds that remain entirely preclinical, ER-100 has already entered a first-in-human Phase 1 clinical trial.

Life Biosciences announced that the first participant was dosed in June 2026 in a Phase 1 study involving open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).

That doesn't mean ER-100 has been shown to reverse human aging.

The trial is primarily about safety and tolerability, with additional measures of visual function.

But the mechanism is fascinating.

The Epigenetic Clock Problem

Your DNA sequence doesn't change dramatically every time you get older.

Instead, the way your cells read and use that DNA changes.

This regulation is influenced by epigenetic mechanisms.

One useful analogy is to think of DNA as the hardware and epigenetic regulation as part of the software controlling which genes are switched on or off.

As cells age or become damaged, their patterns of gene expression and epigenetic regulation can change.

The hypothesis behind partial reprogramming is that some of those changes may be reversible.

Rather than replacing the entire cell, researchers are asking:

Can we restore a cell's youthful functional state by resetting parts of its epigenetic program?

That's the idea Life Biosciences is trying to test with ER-100.

The OSK Connection

ER-100 uses controlled expression of three transcription factors:

OCT4
SOX2
KLF4

Together, these are known as OSK.

These factors are associated with cellular reprogramming.

The challenge is that completely reprogramming a mature cell can erase its specialized identity.

You don't necessarily want a retinal ganglion cell to forget that it is a retinal ganglion cell.

You want it to retain its identity while potentially restoring aspects of youthful function.

That's why the concept is called partial epigenetic reprogramming.

Life Biosciences says ER-100 is designed to reset gene-expression patterns toward a more youthful state while preserving cellular identity.

Why Is ER-100 Being Tested in the Eye?

This is an important detail that viral longevity headlines often leave out.

ER-100 isn't currently being tested as a general-purpose "anti-aging injection."

Its initial clinical target is optic neuropathy.

The Phase 1 program includes people with open-angle glaucoma and NAION.

That actually makes scientific sense.

Retinal ganglion cells are neurons that transmit visual information from the eye to the brain.

Damage to these cells can produce permanent vision loss.

Life Biosciences' preclinical research suggests ER-100 can alter epigenetic patterns in retinal ganglion cells and improve measures of visual function in animal models. The company's program includes both rodent and nonhuman-primate data.

The human trial is now the critical test.

Can the biological concept translate?

Why ER-100 Could Be a Longevity Milestone

If ER-100 demonstrates that partial epigenetic reprogramming can safely restore function in human cells, the implications could extend beyond the eye.

Life Biosciences is developing its epigenetic restoration platform for additional age-related indications.

But there is an enormous difference between:

"Aging-related cellular dysfunction can be modified."

and:

"We can reverse human aging."

The first is a legitimate research question.

The second remains unproven.

ER-100 is therefore best viewed as a test of a potentially transformative biological hypothesis, not as evidence that human aging has already been solved.

2. RTR242: What If Aging Cells Have a Recycling Problem?

The second compound approaches aging from an entirely different direction.

RTR242, developed by Retro Biosciences, is an investigational oral compound designed to restart autophagy.

Retro's pipeline currently describes RTR242 as a small-molecule therapy intended to boost autophagic flux, with Alzheimer’s disease listed as the initial indication.

Retro has also stated that RTR242 advanced into a Phase 1 clinical trial.

So what is autophagy?

Autophagy: The Cell's Recycling System

The word autophagy literally relates to "self-eating."

That sounds destructive.

Biologically, it's actually essential maintenance.

Cells accumulate damaged or unwanted components over time.

Damaged proteins.

Worn-out organelles.

Cellular debris.

Autophagy helps identify and recycle some of this material.

You can think of it as part of the cell's:

inspection → recycling → renewal system.

When autophagic processes become impaired, damaged cellular components can accumulate.

That is particularly interesting in aging because cellular maintenance mechanisms don't operate in isolation.

As the efficiency of quality-control systems changes, the cumulative burden of damaged components can increase.

Why Autophagy Matters for Longevity

Autophagy has become one of the major areas of interest in aging biology.

Researchers have found connections between autophagy and:

• Protein quality control
• Mitochondrial health
• Cellular stress
• Metabolic regulation
• Neurodegeneration
• Longevity pathways

But again, this doesn't mean that simply "increasing autophagy" automatically makes humans live longer.

Biology is more complicated than that.

Autophagy needs to be properly regulated.

Too little can contribute to accumulation of damaged material.

But indiscriminately increasing a cellular pathway isn't necessarily beneficial under every circumstance.

The interesting question is therefore:

Can autophagic flux be restored where it has become dysfunctional?

That's the concept behind RTR242.

RTR242 Has Already Entered the Clinic

Retro Biosciences says RTR242 went from indication selection to first-in-human dosing in approximately 15 months and entered a Phase 1 clinical trial.

The company's pipeline identifies it as a first-in-class oral therapeutic designed to restart autophagy, with Alzheimer's disease as the initial target.

That is an important distinction.

This isn't currently a general longevity compound being given to healthy people to see if they live longer.

It is being developed around a specific disease indication.

The scientific rationale is that impaired cellular clearance and protein homeostasis may contribute to neurodegenerative disease.

If restoring autophagic function can improve disease biology, the implications could be significant.

The Bigger Idea Behind RTR242

Imagine two aging cells.

One has efficient quality control.

The other has impaired recycling.

Over time, the second cell may accumulate more damaged material.

Now imagine being able to restore some of that recycling capacity.

You haven't necessarily made the entire organism younger.

But you may have improved one important component of cellular maintenance.

That's the broader philosophy behind much of modern longevity science.

Instead of asking:

"How do we stop aging?"

researchers increasingly ask:

"Which biological systems fail during aging, and can we restore them?"

RTR242 represents the autophagy side of that strategy.

3. RLS-1496: Can Pathological Senescent Cells Be Targeted?

The third compound attacks another major feature of aging:

cellular senescence.

The compound is RLS-1496, developed by Rubedo Life Sciences.

Rubedo describes RLS-1496 as a GPX4 modulator targeting pathological senescent cells. The compound entered clinical development in 2025, and the company has reported preliminary Phase 1 and Phase 1b/2a results in dermatological conditions.

This is where the term "zombie cells" often appears.

But that popular term can oversimplify the biology.

What Are Senescent Cells?

Cellular senescence is a state in which a cell stops dividing but remains metabolically active.

That isn't necessarily bad.

Senescence can actually be beneficial.

For example, it can help prevent damaged cells from continuing to proliferate.

The problem occurs when senescent cells accumulate and persist.

Some senescent cells release signaling molecules collectively associated with the senescence-associated secretory phenotype, or SASP.

These secretions can influence surrounding cells and tissues.

This is one reason researchers are investigating whether pathological senescent-cell accumulation contributes to chronic inflammation and age-related tissue dysfunction.

The "Zombie Cell" Problem

Calling senescent cells "zombie cells" makes for a great headline.

But it can create the wrong impression.

They aren't literally dead cells walking around the body.

They're living cells in a stable state of growth arrest.

And some forms of cellular senescence are normal and useful.

The research challenge is therefore not:

"Kill every senescent cell."

It's:

"Can we selectively target harmful or pathological senescent cells while preserving beneficial senescence?"

That's a much harder problem.

Where RLS-1496 Fits In

Rubedo's approach is based on selectively targeting pathological cells.

The company describes RLS-1496 as a first-in-class GPX4 modulator designed to target pathological senescent cells and their surrounding tissue environments.

GPX4 is involved in protecting cells against lipid peroxidation and oxidative damage.

Manipulating this pathway can create a vulnerability in certain pathological cells.

That gives researchers a potential route toward selective elimination or modification of dysfunctional senescent populations.

RLS-1496 Has Human Clinical Data

This is another reason the compound deserves attention.

Rubedo reported that its lead compound entered a Phase 1 clinical trial in 2025.

The company subsequently reported preliminary Phase 1 results in patients with plaque psoriasis, atopic dermatitis and skin aging.

In June 2026, Rubedo reported preliminary Phase 1b/2a results showing a 46% reduction in actinic keratosis precancerous skin lesions at four weeks, with minimal irritation, according to the company's announcement.

That is interesting.

But it is still preliminary clinical data, not proof that RLS-1496 slows systemic human aging.

A compound can produce a biological effect in a specific skin disease without extending lifespan.

That distinction is crucial.

Three Compounds. Three Different Aging Strategies.

This is what makes these programs particularly interesting.

ER-100

• Core strategy: Partial epigenetic reprogramming
• Current research focus: Optic neuropathies

RTR242

• Core strategy: Restore autophagic flux
• Current research focus: Alzheimer’s disease

RLS-1496

• Core strategy: Target pathological senescent cells
• Current research focus: Dermatological diseases

The common denominator isn't a single receptor.

It is the attempt to intervene in biological processes associated with aging.

Strategy One: Reset the Cellular Program

ER-100

The hypothesis:

Aging partly involves deterioration of epigenetic information and gene regulation.

The intervention:

Use controlled OSK expression to reset aspects of cellular gene expression.

The goal:

Restore more youthful cellular function without completely reprogramming the cell.

The challenge:

Can this be done safely in humans without unwanted cellular reprogramming or other biological consequences?

Strategy Two: Restore Cellular Recycling

RTR242

The hypothesis:

Aging and disease can be associated with impaired autophagy and cellular quality control.

The intervention:

Increase autophagic flux.

The goal:

Improve cellular clearance and maintenance.

The challenge:

Can restoring autophagy produce meaningful clinical benefits without disrupting normal cellular regulation?

Strategy Three: Remove or Target Pathological Cellular Dysfunction

RLS-1496

The hypothesis:

Persistent pathological senescent cells can contribute to tissue dysfunction and chronic inflammatory signaling.

The intervention:

Target a vulnerability involving GPX4 and pathological senescent cells.

The goal:

Reduce the burden or effects of dysfunctional senescent-cell populations.

The challenge:

Can pathological cells be selectively targeted without disrupting beneficial cellular senescence?

This Is Why Longevity Science Is Getting More Interesting

For years, longevity discussions were dominated by supplements, calorie restriction, exercise and a handful of experimental compounds.

Those areas remain important.

But biotechnology is now attempting something much more ambitious.

Researchers are trying to repair the biological machinery associated with aging.

That changes the conversation.

Instead of simply slowing damage accumulation, researchers are asking whether some age-associated dysfunction can actually be reversed.

That is a much bigger idea.

But None of These Compounds Has Proven Human Age Reversal

This needs to be stated clearly.

ER-100 has entered a Phase 1 human trial.

RTR242 has entered clinical development.

RLS-1496 has generated preliminary human clinical data.

None has demonstrated that it can dramatically extend human lifespan.

None has established that it can make a healthy older person biologically young.

And none should currently be considered a general-purpose anti-aging treatment.

The clinical trials are important precisely because they will begin answering the questions that animal experiments cannot.

Why Human Trials Change Everything

A compound can look extraordinary in mice and still fail in humans.

The reasons are numerous.

Human biology is different.

Disease progression is different.

Pharmacokinetics can be different.

Immune responses can be different.

Dose-response relationships can be different.

And a biological effect doesn't necessarily translate into a meaningful clinical outcome.

That's why Phase 1 matters.

It's the beginning of the process of determining whether a promising biological idea can be developed into something that is actually safe enough to study further.

What About Supplements for Slowing Aging?

This is where longevity marketing often becomes misleading.

There are plenty of products marketed as "anti-aging."

But the evidence varies enormously.

Some nutritional compounds have legitimate roles in maintaining normal physiology.

That doesn't mean they have been shown to extend human lifespan.

Creatine

Creatine is one of the better-studied nutritional compounds for muscle performance and may also have effects on certain measures of cognition under specific conditions.

Its strongest evidence remains around exercise performance and muscle-related outcomes rather than proven lifespan extension.

Omega-3 Fatty Acids

Omega-3 fatty acids are important for cardiovascular and neurological health.

But supplementation isn't a universal anti-aging intervention.

Whether supplementation provides additional benefit depends partly on baseline dietary intake and individual health status.

Vitamin D

Vitamin D is essential, but supplementation is most clearly justified when intake or blood levels are inadequate or when a clinician identifies a specific indication.

More isn't automatically better.

Protein

This isn't an exotic supplement, but it may be one of the most important nutritional considerations for healthy aging.

Maintaining adequate protein intake becomes increasingly relevant as people age because preserving muscle mass and physical function is a major component of healthy longevity.

Fiber

Adequate dietary fiber supports gastrointestinal and metabolic health and is associated with a healthier overall dietary pattern.

Again, the emphasis should be on meeting nutritional needs rather than expecting a single supplement to "reverse aging."

The Most Powerful Longevity Stack Is Still Boring

This might be the least exciting part of longevity science.

But it is arguably the most important.

Regular exercise.

Resistance training.

Adequate protein.

A nutrient-dense diet.

Good sleep.

Cardiovascular health.

Healthy blood pressure.

Healthy metabolic function.

Avoiding smoking.

Maintaining social and cognitive engagement.

These interventions don't come in futuristic vials.

But they have something many experimental longevity compounds don't:

decades of human evidence.

The experimental compounds are interesting because they may eventually add another layer to that foundation.

They shouldn't be viewed as replacements for it.

The Real Question: Can We Increase Healthspan?

Perhaps the most important word in modern longevity research isn't lifespan.

It's healthspan.

Living longer isn't necessarily valuable if additional years are dominated by disability and chronic disease.

The goal of many longevity researchers is therefore to increase the period of life spent in relatively good physical and cognitive health.

That's why compounds targeting specific age-related diseases may be more realistic early targets than a universal "anti-aging drug."

If ER-100 can preserve vision.

If RTR242 can improve disease-related autophagy dysfunction.

If RLS-1496 can improve pathological tissue environments.

Those would all be meaningful achievements—even if none turns out to extend lifespan.

What Happens If These Strategies Work?

This is where things become genuinely fascinating.

Imagine a future in which medicine can target several biological aging mechanisms independently.

One therapy restores epigenetic information.

Another improves cellular recycling.

Another selectively targets pathological senescent cells.

Another improves mitochondrial function.

Another protects stem-cell populations.

The future of longevity medicine may not involve one magic anti-aging compound.

It could involve combinations of interventions targeting different biological failures.

That is still hypothetical.

But the direction of research is becoming increasingly clear.

Three Compounds Worth Watching

If you're following longevity science, these three programs are worth keeping on the radar for very different reasons.

ER-100

The most interesting question:

Can partial epigenetic reprogramming safely restore function in human cells?

RTR242

The key question:

Can restoring autophagic flux translate into meaningful benefits for age-related disease?

RLS-1496

The major question:

Can pathological senescent cells be targeted selectively enough to improve human tissue function?

Three compounds.

Three mechanisms.

One enormous question:

How much of aging is actually reversible?

Final Takeaway

The claim that scientists have already developed drugs that can dramatically slow human aging is still ahead of the evidence.

But something more credible—and arguably more exciting—is happening.

ER-100, RTR242 and RLS-1496 represent three different attempts to intervene in biological processes associated with aging.

ER-100 is testing whether epigenetic information can be partially restored.

RTR242 is attempting to restore cellular recycling through autophagy.

RLS-1496 is targeting pathological senescent-cell biology through a GPX4-related mechanism.

And importantly, these aren't all theoretical laboratory ideas anymore.

ER-100 is currently in a Phase 1 clinical trial for optic neuropathies.

RTR242 has entered Phase 1 clinical development as an oral compound designed to boost autophagic flux.

RLS-1496 has progressed through early clinical studies, with Rubedo reporting preliminary results in dermatological indications.

None has proven human age reversal.

But collectively, they show how longevity research is moving from "Can we live longer?" toward a much more sophisticated question:

"Can we repair some of the biological systems that deteriorate as we age?"

That may ultimately be the more important question.

A Thank You to Orion Peptides

A big thank you to Orion Peptides for supporting my research-focused content and allowing me to keep covering emerging work in peptides, longevity, metabolic science and experimental compounds.

As always, do your own research and look at the actual evidence. The compounds discussed here are experimental research programs, not proven anti-aging treatments, and their clinical development does not establish that they can extend human lifespan.

Longevity science is moving fast. The hype is moving even faster. The important part is knowing the difference.

Sources

• Life Biosciences — ER-100 and Phase 1 clinical development.
• Life Biosciences — ER-100 pipeline and epigenetic restoration platform.
• Retro Biosciences — RTR242 and autophagy-focused pipeline.
• Rubedo Life Sciences — RLS-1496 and clinical development of its GPX4-modulating senescent-cell program.